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Abstract
The sialic acid present in the protective surface mucin coat of Trypanosoma cruzi is added by a membrane anchored trans-
sialidase (TcTS), a modified sialidase that is expressed from a large gene family. In this work, we analyzed single domain
camelid antibodies produced against trans-sialidase. Llamas were immunized with a recombinant trans-sialidase and
inhibitory single-domain antibody fragments were obtained by phage display selection, taking advantage of a screening
strategy using an inhibition test instead of the classic binding assay. Four single domain antibodies displaying strong trans-
sialidase inhibition activity against the recombinant enzyme were identified. They share the same complementarity-
determining region 3 length (17 residues) and have very similar sequences. This result indicates that they likely derived from
a unique clone. Probably there is only one structural solution for tight binding inhibitory antibodies against the TcTS used
for immunization. To our surprise, this single domain antibody that inhibits the recombinant TcTS, failed to inhibit the
enzymatic activity present in parasite extracts. Analysis of individual recombinant trans-sialidases showed that enzymes
expressed from different genes were inhibited to different extents (from 8 to 98%) by the llama antibodies. Amino acid
changes at key positions are likely to be responsible for the differences in inhibition found among the recombinant
enzymes. These results suggest that the presence of a large and diverse trans-sialidase family might be required to prevent
the inhibitory response against this essential enzyme and might thus constitute a novel strategy of T. cruzi to evade the host
immune system.
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Introduction
Unicellular eukaryotic pathogens have developed a variety of
mechanisms to survive in the multicellular organisms that they
parasitize [1]. Some of these mechanisms involve surface/shed
molecules required to invade cells from the host and/or to evade
the host immune response. The human pathogen Trypanosoma
cruzi, the agent of the American endemic Chagas disease, has two
essential mechanisms to survive in the mammalian host: an
intracellular stage and the presence of a diverse surface membrane
coat (reviewed in [2]). This coat is made of mucins that are highly
glycosylated proteins expressed from a large gene family (reviewed
in [3]). The coordinate expression of a large repertoire of mucins
containing variable regions in the mammal stages of the T. cruzi
life cycle suggests a possible strategy to delay the host immune
response [3]. The mucin sugar moiety contains sialic acid that is
implicated in key aspects of parasite-host interactions such as cell
adhesion and invasion [4], and resistance to non-specific
complement attack [5]. Since trypanosomes are unable to
synthesize sialic acid, sialylation of mucins is possible due to the
activity of T. cruzi trans-sialidase (TcTS), a modified sialidase that
instead of hydrolyze sialic acid, transfer the sugar from host
glycoconjugates to a-galactoses present in mucins of the parasite
surface (reviewed in [6]). The three-dimensional structure and the
catalytic mechanism of the enzyme were recently determined [7–
10]. TcTS has a globular core with two domains connected by a
long a-helix. The N-terminal domain has a six bladed b-propeller
fold and contains the catalytic site. The C-terminal domain shows
a lectin-like topology and has not any activity reported until now.
In addition to the globular core of the protein, there is a variable
number of C-terminal highly antigenic 12 amino acid repeated
motif known as SAPA (shed acute phase antigen) [6,11]. This
motif allows the enzyme to remain in blood [12,13]. Strong anti-
SAPA humoral immune response is observed during the acute
PLoS ONE | www.plosone.org 1 October 2008 | Volume 3 | Issue 10 | e3524phase of Chagas’ disease [14,15]. TcTS is encoded in a large gene
family of about 140 members, the protein products differing by
about 5% in their primary sequence. Half of the gene family
members code for inactive proteins due to a mutation in the active
site nucleophile Tyr342 by a His [16,17]. In addition, there are
about 1000 genes that were named ‘‘trans-sialidase-like’’ because
they have about 30–80% of identity to trans-sialidase genes but
lack enzymatic activity [6]. TcTS is a relevant factor in the
infection and pathogenesis of T. cruzi. Recently, it has been
demonstrated that TcTS is responsible of inducing transient
thymic aplasia via apoptosis. This effect could allow the avoidance
of the host immune system by the parasite [18]. Given the essential
roles of TcTS in infection and pathogenesis, this enzyme is a good
target for the development of alternative chemotherapy agents
against the parasite. Nevertheless, small compounds with high
inhibitory activity for trans-sialidase are not currently available. A
sialidase inhibitor, 2,3-didehydro-2-deoxy-N-acetylneuraminic ac-
id (DANA), an analog to the oxocarbenium transition state of the
reaction, is 100-fold less effective toward TcTS (Ki=10 mM) than
to bacterial and viral sialidases [19]. Characterization of
alternative acceptor molecules, lactose derivatives, allowed the
finding of lactitol. This monosaccharide is a better sialic acid
acceptor than conventional substrates like lactose. Lactitol partially
prevents parasite sialylation and invasion into host cells [20] and
the apoptotic effect of TcTS on cells of the immune system [21].
Antibodies able to neutralize TcTS activity are normally found
in patients with chronic Chagas’ disease and animals infected with
T. cruzi [15,22,23]. However, the onset of this antibody response is
delayed until the end of the acute phase and coincides with a
decline in parasitemia levels [15]. Anti-trans-sialidase activity has
been detected in the sera of infected patients using a very specific
and sensitive assay, named trans-sialidase inhibition assay (TIA)
[24]. A monoclonal antibody that neutralizes TcTS activity was
recently obtained. Passive transfer of this antibody to infected
animals prevents TcTS induced thrombocytopenia [25].
Despite the large structural and functional diversity of the
mammalian antibody repertoire, conventional antibodies (i.e.
heterotetramers of two light chains and two heavy chains) acting
as competitive enzyme inhibitors are scarcely found in bibliogra-
phy. They recognize enzymes (and globular proteins in general) by
flat complementary surfaces composed by loops of both the heavy
and light variable domains. As the active site of TcTS is located in
a deep cleft of the protein, it is difficult to obtain a convex binding
surface to reach it by experimental immunizations that elicit
conventional antibodies [25,26]. Camelidae, besides the conven-
tional antibodies, also express heavy-chain antibodies, homodi-
mers that consist of only heavy chains [27]. Their variable region,
named VHH, is the smallest natural antigen-binding fragment
(,16,000 Da), and being just one polypeptide chain it is especially
suitable for engineering. In particular, longer complementarity-
determining region 3 (CDR3) loops protruding from the binding
site and the deviation of CDR conformations from the equivalent
human or mouse loop structures, suggest that camelid single
domain antibodies might have different strategies of binding
[26,28]. In contrast to the antigen binding fragments of
conventional antibodies, VHHs are often potent inhibitors of
enzymes [26,28]. Some long CDR3 loops protruding to the active
site of the enzyme are responsible for that inhibition.
In this work we show that inhibitory antibodies against trans-
sialidase can be obtained by phage display selection of single-
domain antibody fragments from immunized llamas. These
antibodies inhibited the recombinant TcTS that was used for
immunization. However, they were unable to inhibit partially
purified TcTS from T. cruzi parasites, which are naturally
expressed from different genes. Our results suggest that subtle
mutations in members of the TcTS family prevent the complete
neutralization of the parasite enzymatic activity.
Results
Immunized llamas show polyclonal inhibitory response
against TcTS activity in sera
Two llamas were immunized using different recombinant TcTS
constructions. Llama 7006, was immunized with pTcTSD1443
(lacking the 1443 epitope and retaining the SAPA repeats). This
recombinant protein was used since deletion of the internal
epitope between amino acids 433 and 447, called epitope 1443,
increases the production of neutralizing antibodies in mouse
models of infection [29,30]. The second camelid, named llama
9210, was immunized with protein from the clone pTrcTS611/2
(entire globular core of TcTS without SAPA repeats) [31]. Llama
9210 showed a late TcTS inhibitory response and at lower level
than llama 7006 (data not shown). Due to the high polyclonal
inhibitory response detected in serum from llama 7006 after the
fourth immunization, we engaged in the construction of a VHH
library from the RNA of lymphocytes isolated from this animal
fifteen days after the last immunization (Figure 1). The absence of
1443 epitope and/or the presence of SAPA repeats that increase
the half-life in blood could be responsible for the difference in the
inhibitory response between both llamas.
Screening for inhibitory clones
The quality of the library, composed by 2610
6 single clones,
was checked by sequencing fourteen randomly chosen clones,
which showed high variability in nucleotide sequence (Figure 2A).
Ninety-four phage-VHH clones obtained from the first round of
panning were analyzed by TIA (trans-sialidase inhibition assay, see
Materials and Methods) using TcTS611/2. This preliminary
TcTS inhibition screening allowed us to identify three clearly
defined groups of VHHs: non-inhibitors (NI), weak inhibitors (WI)
and strong inhibitors (SI) represented by 74, 13 and 7 clones,
respectively (Figure 3A). Since the total percentage of inhibitors
(21%) is smaller than the percentage of binders (71%, Table 1), the
use of a screening inhibition assay resulted in a powerful strategy
Figure 1. Inhibition of TcTS activity by llama 7006 serum. Serial
dilutions of pre-immune and post-recombinant TcTSD1443-SAPA
immunization sera, were analyzed by TIA as indicated under Materials
and Methods.
doi:10.1371/journal.pone.0003524.g001
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reproducible when testing soluble VHHs (results not shown).
After sequencing, the seven strong TcTS inhibitor clones showed
to correspond to four unique clones (clones SI14, SI52, SI57 and
SI96, Figure 2B). Selected weak inhibitor clones WI58 and WI48
(a conventional IgG VH) were included for further comparison.
As shown in figure 2, none of the SI selected clones appear
among the sequenced prepanning clones (except for prepanning
clone 16), indicating that their selection was not due to
overrepresentation in the library. Besides, prepanning clones
showed a higher diversity in sequence and in the CDRs length
than inhibitory selected clones. Particularly, CDR3 of prepanning
clones range from 9 to 20 amino acids, meanwhile SI clones share
the same CDR3 length (17 residues). A common characteristic of
VHHs is the presence of long CDR3 loops, which confer increase
diversity to the binding site of these single domain antibodies.
Clones displaying strong inhibition capacity had very similar
sequences, showing that they derived, likely, from the same
original clone that had undergone different somatic mutations that
affect a pair of CDR residues and framework region 3. In contrast,
clones WI48 and WI58, which had low inhibition capacity, had
different CDR3 sequence and length, indicating that derived from
different clones.
Single domain llama antibodies that inhibit recombinant
TcTS activity recognize a conformational epitope with
affinities in the nanomolar range
Figure 3B shows the inhibitory activity displayed by soluble
purified VHHs against recombinant TcTS611/2. Clone SI14
showed the strongest inhibition activity while clone WI58 showed
lower TcTS inhibition activity. We measured the affinities of
VHH-TcTS complexes using a biosensor (Table 2). The four
selected SI clones showed similar affinities for TcTS, with KD
values in the high nanomolar range (22 to 86 nM). Thus, there is a
correlation between affinity and inhibition capacity among VHHs
since clone SI14, which showed the higher affinity to TcTS on
biosensor analysis has the higher inhibition capacity. To analyze
whether inhibitory VHH recognize conformational or linear
epitopes, purified VHHs spotted onto a nitrocellulose membrane
were reacted with native and denatured recombinant TcTS611/2.
Figure 2. (A) Alignment of the sequences of 14 randomly chosen clones from the library before panning (pre-panning clones are labeled pp) and (B)
Sequence analysis of the six post-panning selected VHHs.The 4 strong inhibitors (SI) clones are shown in clear gray background. Lengths in CDR3 are
shown in dark gray background. Clone WI48 is a conventional IgG (*) and its characteristic residues are marked in black. Spaces denote identical
residues and dashes denote deletions. Numbering and CDR designations are according to IMGT numbering system [46].
doi:10.1371/journal.pone.0003524.g002
Trans-Sialidase Diversity
PLoS ONE | www.plosone.org 3 October 2008 | Volume 3 | Issue 10 | e3524All VHHs bound native TcTS but did not recognize denatured
TcTS (Figure 3C) indicating that the selected inhibitory VHHs
recognize discontinuous TcTS epitopes.
Strong inhibitor VHHs recognize an epitope overlapped
to the active site
Tyr119 and Trp312 are key residues for the activity of the
enzyme since proteins mutant TcTS Tyr119Ser and Trp312Ala
loose 90% and 100% of transfer activity, respectively [9,10,32].
We measured the binding affinity of VHHs to mutant
TcTSTrp312Ala and TcTSTyr119Ser. VHHSI14 binds to both
mutants with approximately ten times lower affinity compared to
recombinant TcTS611/2 (Table 2), indicating that VHHSI14
recognizes residues near or in the active site of TcTS.
The decrease in the binding affinity of VHHSI14 to mutant
TcTS prompted us to test the effect of the conformational change
of Tyr119. Upon binding of DANA to TcTS active site, residue
Tyr119 moves away from catalytic center and it is positioned in
front of the indole ring of Trp312 [8,33]. To study if llama
inhibitory single domain antibodies sense the TcTS conforma-
tional change produced by DANA, we analyzed the binding
Figure 3. (A) Screening of VHH library. 94 individual phages-VHH clones were tested by TIA using TcTS611/2. Three clear groups are observed, NI:
non-inhibitors, WI: weak inhibitors, SI: strong inhibitors. Each point represents phages prepared from a single colony. TIA values lower than 25% were
considered as negative. (B) Purified VHHs inhibit recombinant TcTS activity. A fixed mass of 0.5 ng of purified TcTS611/2 was preincubated with
increasing concentrations of each VHH and trans-sialidase activity was analyzed by TIA. The values represent the average of at least three
independent determinations. (C) The selected VHHs recognize conformational epitopes. Recombinant proteins, all carrying a His-tag, were spotted onto
nitrocellulose membrane as indicated in the panel 4: A) SI14, B) WI58, C) SI52, D) SI96, E) SI57, F) TcTS611/2, G) Denatured TcTS611/2 in 0.1% SDS, H)
Non-related (non-anti-TcTS) VHH. Panel 1 and panel 2 were incubated with native TcTS and denatured TcTS in 0.1% SDS, respectively. Both panels
were treated with rabbit anti-TcTS serum. Panel 3 was processed with a mouse anti-Histidine antibody as a control for protein immobilization. Filters
were revealed with the corresponding HRP-conjugated-anti-serum for chemiluminescence generation.
doi:10.1371/journal.pone.0003524.g003
Table 1. Panning of the library and its evaluation by phage-
ELISA.
1
st round 2
nd round 3
rd round
Input 7.3610
12 1.6610
13 8.2610
12
SBO
a 3.8610
8 3.7610
10 1.6610
10
NSBO
b 3.4610
7 2.4610
10 1.0610
9
TcTS binders/total clones 10/14 (71%) 16/32 (50%) 3/30 (10%)
aSBO: specific binding output.
bNSBO: Non-specific binding output
Numbers are expressed as colony forming units.
doi:10.1371/journal.pone.0003524.t001
Table 2. Affinities of TcTS-VHH complexes (IAsys biosensor
analysis).
TcTS VHH clone
Kon
(10
5 M
21s
21) Koff (10
23 s
21) KD (10
29 M)
a
611/2 SI14 1.1960.10 2.6560.04 22.2760.24
SI52 1.4960.05 10.30 60.24 69.0360.43
SI57 1.6560.13 14.27 60.20 86.3461.92
SI96 3.5260.28 17.0560.21 48.4460.44
Trp312Ala SI14 0.6260.04 14.5060.30 230.10617.22
Try119Ser SI14 0.7460.03 14.7060.30 197.16612.11
aThe KD value was determined as the Koff/Kon ratio.
doi:10.1371/journal.pone.0003524.t002
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absence of this ligand. As seen in Figure 4A, the signal obtained
upon TcTS611/2 binding increased in the presence of DANA.
This increment in the signal is similar to the effect of increasing ten
times the concentration of TcTS. As shown Figure 4B, there is a
linear correlation between the increase in VHHSI14-TcTS
binding response and the DANA concentration. This effect was
similarly observed in all the four SI VHHs selected clones (data not
shown). This result implies a higher affinity of the SI clones for the
conformation adopted by the enzyme upon binding of DANA,
which would then enhance the SI VHHs competitive inhibition
activity. Interestingly that sialic acid is present at high concentra-
tions in blood [34], thus it is possible that the immune system
recognize TcTS in this particular acceptor-bound conformation.
In summary, we obtained different results suggesting that this
family of single domain llama antibodies recognize with high
affinity an epitope close or overlapped to the active site of the
enzyme.
Epitope mapping analysis of the binding of the SI VHHs to
recombinant TcTS is shown in Figure 5. Comparing free TcTS
and DANA-TcTS structures (Figure 5A and 5B), it can be seen
that Tyr119 suffers a conformational change upon binding to
DANA [8,33].
Single domain antibodies fail to inhibit the natural trans-
sialidase
VHHSI14 was tested against supernatants of Cl-Brener T. cruzi-
infected cell cultures containing TcTS released from the
trypomastigote stage of the parasite. Surprisingly, VHHSI14
failed to inhibit the enzyme present in parasite supernatants while
a strong inhibition activity toward the recombinant TcTS611/2
used as a control was observed (figure 6A). Supernatants from
three different strains were assayed in the presence of an excess of
VHHSI14 antibody, showing similar results (Table 3). The lack of
inhibition by VHHSI14 antibody was not due to the presence of
any compound in the medium since recombinant TcTS added in
the reaction was neutralized (Table 3). Similar negative results
were observed with live Cl-Brener trypomastigotes containing
TcTS linked to the membrane surface of the parasites (data not
shown). To analyze if the ausence of inhibition was due to the
univalent nature of VHHs, we increased the avidity of this
Figure 4. DANA increased the VHH binding to recombinant TcTS. Soluble TcTS611/2 was added in the presence or the absence of DANA to a
cuvette derivatized with VHH. (A) Binding kinetics of VHHSI96 to TcTS in the presence or absence of 10 mM DANA. (B) Response at the equilibrium of
VHHSI14-TcTS in different concentrations of DANA. The addition of DANA did not affect the baseline.
doi:10.1371/journal.pone.0003524.g004
Figure 5. The epitope recognized by inhibitory llama antibod-
ies maps to the TcTS catalytic site. View of the TcTS active site
shown as surface representation using the program Chimera. (A) Free
TcTS, (B) DANA-TcTS (shows the conformational change upon binding
of DANA to TcTS) and (C) shows a 90u rotation of TcTS-DANA structure
highlighting the arginine 311 residue protruding from the active site.
PDBs used are 1MS4 and 1MS8. Residues involved in the catalytic site
are colored as follows: mutated residues that were analyzed in this work
(Trp312 and Tyr119) in red, other catalytic amino acids (Arg35, Asp59,
Asp96, Met98, Arg314, Arg245, Glu230 and Tyr342) in yellow, space-fill
model of DANA in green and Arg311 in blue.
doi:10.1371/journal.pone.0003524.g005
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displaying ten VHH domains per assembly, taking advantage of
the decameric structure of Brucella spp. lumazine synthase [35].
This assembly allowed to increase 10 times the avidity of
Figure 6. (A) Natural TcTS was not inhibited by VHHSI14. Comparison of VHH114 inhibition activity of the TcTS present in supernatants from Cl-Brener
T. cruzi-infected cell cultures versus a recombinant TcTS611/2 enzyme. The decameric form of VHHSI14 was used. The values represent the average of
two independent determinations. (B) Independent recombinant TcTSs are inhibited to different extents by VHHSI14. A fixed mass of 0.5 ng of different
purified TcTSs from T. cruzi were preincubated with increasing concentrations of VHHSI14 decameric form and the remaining trans-sialidase activity
was analyzed by TIA. The values represent the average of at least three independent determinations.
doi:10.1371/journal.pone.0003524.g006
Table 3. Effect of VHHSI14 on natural TcTS from T. cruzi trypomastigotes.
TcTS activity
a
Total activity
Preincubated with
VHHSI14 (40 ng)
Preincubated with
lactitol 1 mM
b
Recombinant TcTS611/2
c 32796314 6216212 (81.1)
d 4226218 (87.1)
Natural TcTS
e
Cl-Brener strain 11546135 1017671 (11.9) 188633 (83.7)
RA strain 16536184 15766162 (4.6) ND
f
Villegas strain 1960690 15626145 (22.8) 514670 (73.7)
Natural TcTS plus recombinant TcTS
Supernatant (Cl-Brener) 23186288 20826272 (10.2) ND
Recombinant TcTS611/2 32866401 6516201 (80.1) ND
Supernatant (Cl-Brener) plus recombinant TcTS611/2 51346109 24616466 (52.1) ND
Cl-Brener trypomastigotes
g 9186168 8346102 (4.8) ND
Inmunoprecipitated TcTS (Cl-Brener)
g
Treated with PNGasa 26326396 24116450 (9.2) 2986198 (88.7)
Untreated with PNGasa 21576237 20796243 (3.6) 3216184 (85.1)
aResults are expressed in CPM (Counts Per Minute) obtained after 1 hour of reaction (by TIA). The values are the mean and standard deviation of at least three
independent experiments.
bLactitol was assayed as positive inhibition control on Natural TcTS.
cRecombinant TcTS was assayed as positive control of inhibition in every single test.
dParenthesis indicate percentage of inhibition of TcTS activity that remnant CPM represents .
eSupernatant from cell culture derived trypomastigotes were used.
fND: not determinated.
gDecameric form of VHHS14 was used.
doi:10.1371/journal.pone.0003524.t003
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its inhibitory capacity as compared with that of the monomeric
VHHSI14 (data not shown). This construction was assayed against
Cl-Brener trypomastigotes and it was still unable to inhibit the
activity of TcTS present in the surface of parasites (Table 3).
The lack of inhibition of the natural trans-sialidase is due
to differences among members of the enzyme family
A possible explanation for this contradictory result could be the
existence of post-translational modifications present in the natural
enzyme but absent in the recombinant E. coli TcTS enzymes. It is
known that natural TcTS is glycosylated. One of the two possible
N-glycosylation sites, located in residue 114, is close to the active
site (predicted by NetNgly 1.0 server, see figure S2) and it
corresponds with a N-glycosylation observed in residue 115 of
Trypanosoma rangeli sialidase [8,9]. No VHHSI14 inhibitory activity
was seen when natural TcTS was immunoprecipitated from
extracts of Cl-Brener trypomastigotes (the infective form of the
parasite in the mammalian host) using an anti-SAPA antibody and
treated with the high processive enzyme PNGase F. Controls of
the deglycosylation process are shown in figure S1. Thus, it is
unlikely that the presence of sugars in the natural TcTS were the
reason of the lack of inhibition by VHHSI14 (Table 3).
T. cruzi is known to have a large number of TcTS genes, 70 in a
strain of the parasite, expressing enzymatically active proteins
[16]. It is also known that these genes somewhat differ in their
primary sequence. These differences might cause the variations in
the inhibitory effects of antibodies on the TcTS family. To test this
hypothesis, we cloned and expressed five active recombinant
TcTS clones by PCR (see sequences in Figure S2, supplemental
data) using specific primers to amplify the entire globular core of
the enzyme (see Materials and Methods). Figure 6B resume results
of VHHSI14 decameric form tested toward these recombinant
TcTSs clones using TIA assay. The five clones plus the TcTS611/
2, used as a control, were inhibited to different extents by the
VHHSI14 when they were tested under the same experimental
conditions. TcTS-46 and TcTS-49 were poorly inhibited when
increasing amounts of VHHSI14 were added. Both clones have
several changes in their primary sequence as deduced from DNA
sequencing (90.3 and 90.6% of identity respect TcTS611/2, see
Table S1 in supplemental data). TcTS-24 was highly inhibited,
even more than TcTS611/2, the clone whose product was used
for the immunization, while TcTS-12 and TcTS-15 present
intermediate inhibitory levels. Similar results were obtained when
an excess of the other strong inhibitors VHHs were tested with
TcTSs (Table 4). These results suggest that the VHHs antibody
fragments might recognize minor antigenic differences between
natural TcTSs resulting in different inhibition levels.
Next we analyzed the identity of the amino acid residues in the
active site among all TcTS clones tested. All TcTSs that were
inhibited by the camelid antibody have an arginine at position
311, which protrudes from the active site (as is shown in the wild-
type TcTS-DANA complex structure, Figure 5C). In contrast,
both TcTS that were almost not inhibited by VHHSI14 (TcTS-46
and TcTS-49) have a tryptophan residue in position 311 instead of
arginine. We postulate that this bulky tryptophan, among other
differences, might interfere with the binding to antibodies. Since
we found that two mutations at single amino acid positions
strongly affect VHH binding (Table 2), these results are in
agreement with the possibility that differences in amino acid
residues located close to, or in, the active site might result in the
lack or decreased inhibition of some TcTS members by the llama
antibodies.
Discussion
In this work, we report the identification of single domain llama
antibodies against recombinant TcTS that bind a site close or
overlapping the active site of the enzyme. The antibodies had the
expected inhibitory capacities and affinities and were obtained
after one round of phage display selection. Three key factors
allowed the success of the strategy used. First, the immunization of
llamas allowed us to obtain the smallest antibody fragments with
usually protruding long loops that facilitate the access to the active
site cleft of enzymes. Second, the use of engineered TcTS, as
immunogen, that increased the probabilities of raising antibodies
that recognize the enzyme active site. Third, the use of a strategy
that is based on a soluble inhibition screening test, instead of the
classic binding assay to select a phage display library. Clones
showing strong inhibitory activities represent approximately 7% of
the selected clones, which is a logical result taking into account
that TcTS is a large protein (70,000 Da). Thus, a sensitive phage-
TIA assay allowed us for a simple, fast and very efficient selection
of clones with inhibitory capacity. All seven selected clones
represent four different single domain antibodies derived from the
same clone, as can clearly be seen for their high sequence
homology and an identical VDJ recombination sites. The
Table 4. Effect of 200 ng of each strong inhibitor VHH on different TcTS clones from Cl-Brener strain.
TcTS activity
a
TcTS-24 TcTS-611/2 TcTS-15 TcTS-12 TcTS-49 TcTS-46
Total TcTS Activity 208616 1080653 10856110 11956107 506671 260659
VHHSI14-decameric form 564 (97.7)
b 218628 (79.8) 522683 (51.9) 606660 (49.3) 368685 (27.3) 238670 (8.4)
VHHSI14 464 (98.0) 143651 (86.7) 3206105 (70.6) 480643 (59.9) 237677 (53.1) 158642 (39.1)
VHHSI52 464 (98.0) 202637 (81.3) 340659 (68.7) 512685 (57.2) 2586135 (49.0) 159647 (38.9)
VHHSI57 363 (98.4) 181631 (83.3) 204613 (81.2) 512655 (57.2) 248693 (51.1) 177685 (31.7)
VHHSI96 1268 (94.2) 211663 (80.5) 354671 (67.4) 485644 (59.5) 383690 (24.4) 170682 (34.8)
Lactitol 1mM
c 13613 (93.9) 165672 (84.7) 175669 (83.9) 193639 (83.8) 52637 (89.8) 21620 (92.2)
aTrans-sialidase activity was expressed in nmoles of syalil residue transferred to lactose6mg
216min
21 (by TIA). The values are the mean and standard deviation of at
least three independent experiments.
bParenthesis indicate percentage of inhibition of TcTS activity that the remnant activity represents.
cLactitol was used was assayed as positive control of inhibition of TcTS activity.
doi:10.1371/journal.pone.0003524.t004
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one conservative difference at position 115 (Valine to Isoleucine).
Thus, these results suggest that in our library there is only one
structural solution for obtaining antibodies tightly binding to the
recombinant TcTS active site used as immunogen.
VHHs described in the literature recognize globular proteins with
affinities between 20–100 nM [36]. Particularly, camelid fragments
with enzymatic inhibitory capacities [26,36–38] have affinities in the
25621 nM range, showed similar CDR1 and CDR2 length (861.5
and 7.760.7 residues, respectively) and differ in the number of
disulfide bonds and in the CDR3 length from 11 to 24 residues,
resulting in an average of 15.863.6 residues. Thus, our four selected
clones fall within the range of the previously described inhibitory
single domain antibodies since they showed affinities in the 22–
86 nM range and have CDR lengths of 8, 7 and 17 residues for
CDR1, CDR2, and CDR3, respectively. As the four selected VHHs
derive from the same clone, thus it is fair to assume that all of them
bind to the same epitope on TcTS. In coincidence, there is a clear
correlation between affinity and inhibitory capacity among these
four clones, being clone SI14 the one that shows the higher affinity
and also the stronger inhibition capacity.
Site directed mutagenesis of TcTS Tyr119 and Trp312
residues, which are implicated in the enzymatic mechanism of
trans-sialidase activity, decreases about ten times their binding to
the antibodies (Table 2), while the addition of DANA increases
their binding to TcTS (Figure 4). It can be inferred that these
antibodies recognize this surface on the catalytic site. Whether the
longer CDR3 loops of these antibodies penetrate inside the cavity
or, alternatively, the binding of the VHHs does not allow the
access of the acceptor lactose, remains to be demonstrated.
Despite we observed a strong inhibition of the recombinant
TcTS used for immunization by llama single domain antibodies;
they were unable to inhibit the complex mixture of TcTSs
expressed in trypomastigote parasites. Purified VHHs inhibited
recombinant TcTS611/2 by 60–80% and VHHS114 inhibited 8–
98% the enzymatic activity of different recombinant trans-
sialidases. On the other hand, the natural enzyme from Cl-Brener
strain was inhibited only between 3% and 12%. There are several
possible explanations for these apparently contradictory findings.
One is that glycosylation of the natural enzyme, not present in the
enzyme expressed in bacterial systems, might prevent the
interaction of the enzyme with the VHH. This does not seem to
be the case (see Fig. S1). However, we can not completely exclude
the possibility that PNGase failed to fully deglycosylate all of the
different natural TS enzymes. Even if this was the case, these
results do not invalidate those showing that different recombinant
enzymes expressed in bacterial systems are inhibited to different
extents by VHHs, one of the main conclusions of this work. An
alternative explanation is the presence of TcTS-like molecules
lowering the effective concentration of VHHs or the presence of
other inhibitors in the natural enzyme sample. A recombinant
TcTS added to the natural enzyme sample was inhibited,
precluding the previously mentioned possibility. Clearly, it is not
possible at present to find a simple explanation for the above
mention findings, which awaits results from a different approach,
like structural studies, to solve it.
The results obtained in this work, showing that different
recombinant TcTS protein products are inhibited to different
extents by the four VHHs tested, indicate that VHHs could
recognize minor antigenic differences present in the polymorphic
population of natural trans-sialidases, as this enzymatic activity
potentially derives from the simultaneous expression of about 70
different genes [39]. These observations suggest an interesting
hypothesis to explain the possible usefulness for the presence of a
TcTS family. If trans-sialidase activity results from the expression
of a single gene, one antibody clone might be enough to
completely neutralize the enzymatic activity. The simultaneous
expression of a large number of trans-sialidases slightly differing in
primary sequence but not in enzymatic activity might delay the
complete inhibition of the parasite enzyme. In addition to genes
encoding trans-sialidase enzymes, there is a larger number of
trans-sialidase genes (about 1000), coding for proteins with
homologies to trans-sialidase but lacking enzymatic activity. These
non-enzymatic proteins might be further involved in the
distraction of the immune antibody response against active
members of the family [39]. In summary, a large part of the
genome is devoted to encode trans-sialidase and trans-sialidase-like
proteins likely to be involved in the protection against a
neutralizing activity that might prevent parasite development in
the mammalian host.
Presently, we do not know which TcTS amino acid positions are
recognized by the llama antibody VHHSI14 to neutralize enzymatic
activity. Future work, including the determination of TcTS structure
in complex with antibodies will indicate if there are mutational hot-
spots for the generation of TcTS diversity preventing interaction
with antibodies but not affecting the enzymatic activity. However,
structuraland bioinformatic analyses allowedusto identifya key role
of residue 311. Arg311 side chain protrudes in the active site while
both poorly inhibited TcTS (TcTS-46 and TcTS-49) have a bulky
tryptophanatthisposition.Thus,wepostulatethatTrp311wouldbe
responsible for steric hindrance of the VHH binding to the epitope
recognized in the enzyme.
We have previously postulated that the amplification and
divergence of the members of the mucin family covering the
trypanosomal surface are also involved in delay the host immune
response [3]. In this case, coordinate expression of a large
repertoire of mucins containing variable regions in the mammal
stages of the T. cruzi life cycle might delay a lytic antibody
response. In the case of TcTS, coordinate expression of several
enzymatically active proteins having subtle differences at amino
acid positions in or around the active site might delay the immune
response inhibiting the complete enzymatic makeup of the
parasite. Antibodies neutralizing TcTS are detectable in the host
serum later during the infection with T. cruzi [15,24], and through
immunization with recombinant enzymes or DNA [21,25,40–43].
Thus, our model of epitope variation among TcTS members to
prevent an inhibitory response might apply for the early stages of
the infection, period during which the parasite requires the
necessary time to reach the niches inside the host cells.
Materials and Methods
TcTS expression and purification. E. coli strain BL21
(DE3) pLysS (Novagen) was transformed with plasmids
(pTrcHisA, Invitrogen) encoding different TcTS clones. A
dilution of the over night culture was grown until A600nm 1.0–
1.2 in constant agitation at 37uC. To over express TcTS, 0.5 mM
isopropyl-b-D-thiogalactopyranoside (IPTG, Sigma) was added
and growth was continued with constant agitation at 18uC, for 12–
16 hs. Harvested cells were conserved at 280uC until purification.
Bacterial cells were resuspend in 20 mM Tris-HCl pH 8.0, 0.5 M
NaCl, 0.5% triton, 100 mg/ml DNase I, 1 mM
phenylmethanesulfonyl fluoride (Sigma) and sonicated several
times to reduce viscosity in a Brandson 450 sonicator. Supernatant
was ultracentrifugated (45000 rpm, 45 min in a 70Ti rotor),
filtered through 0.22 mm membrane filter and subjected to a Ni++
charged Hi-Trap chelating HP column (Amersham Pharmacia
Biotech). Column was washed with 30 mM imidazole (Sigma) and
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pH 8.0, 0.5 M NaCl. Elution peak was dialyzed against Tris-HCl
pH 8.8, 30 mM NaCl, 1 mM EDTA and further purified by
FPLC anionic exchange (MonoQ, Amersham Pharmacia Biotech).
Elution was done applying a linear gradient of NaCl.
Immunization. Young male llamas (Lama glama)w e r ei n j e c t e d
at days 0, 21, 35 and 56 with 0.5 mg of recombinant TcTSs, using
aluminum hydroxide as adjuvant. Before each boost, blood samples
were collected and the sera were used to ascertain the immune
response from the last immunization. At day 62 anticoagulated
blood was collected and used for mononuclear cell isolation. All
animal procedures were approved by the animal care committee of
the IIB-INTECH in accordance with the guidelines laid out by the
NIH regarding the care and use of animals for research.
Construction of the library. Mononuclear cells were isolated
from llama 7006 heparinized blood by Ficoll-Hypaque (Pharmacia)
gradient centrifugation. Total RNA was purified by TRIZOL
reagent (Pharmacia) and subject to cDNA synthesis. To synthesize
cDNA, 3 mgo fR N Aa n d1 . 5 mgo fo l i g o - d T 30 in 7.5 mlw e r e
incubated for 10 min at 70uC and placed on ice. After a spin down,
0.4 mM dNTPs, RT buffer 1X, 200U M-MLV RT (Promega) and
25U RNAsin (Promega) were added, in a total volume of 25 mla n d
incubated 1 h at 42uC. The reaction was stopped at 70uCfo r1 5mi n .
cDNAs encoding an entire VHH domain and part of the hinge
region were amplified by PCR using primers VH1Back-SfiI or
VH6Back-SfiI in combination with primer Lamb7-NotI or Lamb8-
NotI. Primer VHBack-SfiI anneals to VHHs N-terminal consensus
sequences. Primers Lamb7-NotI and Lamb8-NotI hybridize to part
of the short and long hinge region of the CH2 domain, respectively
[44]. Their sequences are: VH1Back-SfiI: GCT GGA TTG TTA
TTA CTC GCG GCC CAG CCG GCC ATG GCC CAG GTS
MAR CTG CAG SAG TCW GG; VH6Back-SfiI: GCT GGA
TTG TTA TTA TCT GCG GCC CAG CCG GCC ATG GCC
GAT GTG CAG CTG CAG GCG TCT GGR GGA GG; Lamb7-
NotI: G ATG GTG ATG ATG ATG TGC GGC CGC GCT
GGG GTC TTC GCT GTG GTG CG; Lamb8-NotI: G ATG
GTG ATG ATG ATG TGC GGC CGC TGG TTG TGG TTT
TGG TGT CTT GGG. Restriction enzyme sequences are
underlined. The resulting PCR fragments (,450 bp) were purified
from agarose gels (GFX PCR DNA & Gel band purification Kit,
Pharmacia), digested sequentially with SfiI and NotI and repurified.
For phage-display library construction, 5 mg of SfiI-NotI-
digested plasmid pHEN2 and digested fragment were ligated in
a 1:5 ratio during 16 hs at 16uC. Inserts were introduced between
PelB leader signal and His-tag, in frame with pIII capsid protein
gene in the vector pHEN2 [45]. The ligation reaction (200 ml) was
purified with phenol:chloroform:isoamylic alcohol 25:24:1, ex-
tracted twice with chloroform and precipitated with 20 mg
glycogen, 30 ml 2 M AcONa pH 5.2 and 440 ml EtOH for
24 hs at 280uC. The pellet was washed with 70% EtOH, dried,
resuspended in 2 ml of H2O and concentrated with a centricon
YM-3 (Amicon) to 15 ml in sterile milliQ water. Electrocompetent
E. coli XL Blue MRFcells were transformed and library size was
calculated by plating aliquots on LB ampicillin agar. The library
diversity was checked by sequencing.
Phage display. To prepare polyclonal phages, library stock
or cells pre-infected with phages eluted during panning were
grown until A600nm 0.5 and were then infected with at least 10-fold
excess of VCS helper phage (Promega) at 37uC in presence of
glucose 1%. After one hour incubation, cells were washed by
harvesting and resuspending the cells in glucose-free fresh culture
media. After growing over night at 30uC, phages were recovered
from culture supernatant by incubation at 4uC followed of
precipitation in 4% PEG 8,000, 0.5 M NaCl. Pellet was
resuspended in 1 ml sterile PBS/100 ml culture and used for
panning. To enrich the library for the presence of T. cruzi trans-
sialidase binders, panning was performed on 24 well culture plates
(Hamilton). Wells were coated with 2 mg polyclonal rabbit anti-
SAPA antibody for 16 hs at 4uC. After blocking with 3% skim milk
in PBS (SM-PBS), 10 mg TcTSD1443-SAPA were added in 1%
SM-PBS with agitation during 2 hs followed by a similar
incubation with approximately 10
13 VHH-phages. Washing was
done 3 times with PBS between each step. VHH-phage binders
were eluted by incubation with 100 mM glycine-HCl pH 2.2
during 10 min and immediately neutralized with 2 M Tris-HCl
pH 8.0. This procedure was followed by amplification of the
eluted phages and repeated 2 times. Phage titers of input and
output at all steps were estimated by enumeration of ampicillin
resistant colonies obtained from TG1 cells infected with different
phage dilutions (Table 1).
To evaluate the enrichment during panning cycles, the capacity
to bind TcTS of randomly chosen clones from each round was
tested by phage-ELISA. Wells without immobilized protein were
used as non-specific binding control (NSB). Unexpectedly, the
proportion of binders decreased during successive rounds of
panning due to negative selection (Table 1). Given this fact, we
decided to work with phages from the first round of panning.
Production of individual VHH-phages. Plates with
individual clones in culture medium with glucose were grown
3h sa t3 7 uC with agitation, and super infected with VCS helper
phage for 30 min. Cells were pelleted, resuspended in the same
medium without glucose and incubated for 16 hs at 30uC. The
supernatants containing the VHH-phages were used for ELISA or
TIA assays.
Elisa. Plates were sensibilized over night with 200 ng/well of
polyclonal rabbit anti-SAPA antibody. After blocking with 3%
SM-PBS, 250 ng TcTSD1443-SAPA were added in 1% SM-PBS
during 2 hs. Culture supernatant containing phages expressing
VHHs were diluted twofold in 2% SM-PBS and added for 2 hs.
Bound phages were washed with PBS-Tween and revealed with
mouse anti-M13 conjugated to HRP (Pharmacia) dilution 1/
2,000. Substrate (OPD, Sigma) was added, reaction was stopped
with 2 M H2SO4 and A495nm was measured on an ELISA reader
(S960 Metertech Inc.).
Production and purification of soluble VHHs. Phagemid
DNAs recovered from six isolated clones were transformed into E.
coli HB2151 cells. These cells are unable to suppress the amber stop
codon between the cloned VHH and gene III, producing soluble
VHH fragments tagged with C-terminal 6xHis upon induction with
IPTG. After 4 hs induction with 1 mM IPTG, the expressed
proteins were extracted from the periplasmic space through osmotic
shock passing from 500 mM to 125 mM sucrose solution in buffer
200 mM Tris-HCl, 0.5 mM EDTA pH 8. The obtained VHHs
have an apparent MW between 16,000 to 18,000 Da. Further
purification of soluble protein was achieved on Hi-Trap chelating
HP column (Pharmacia). Column was washed with 10 mM
imidazole (Sigma) 0.3 M NaCl in sodium phosphate pH 8.0 and
elution was done using 250 mM imidazole in the same buffer.
Trans-sialidase activity assay. Trans-sialidase activity was
measured as the transfer of sialic acid from 1 mM sialyl-a-(2-3)-
lactose (Sigma) to 12 mM [D-glucose-1-
14C] lactose (55 mCi/
mmol) (Amersham), by 0.5 ng of purified TcTS enzyme in 30 ml
of 20 mM Hepes-Na (pH 7.5), 0.2% BSA, 30 mM NaCl. After
60 min at 25uC, the reaction was stopped by dilution with 1 ml of
water. QAE-Sephadex (Amersham Pharmacia Biotech) was added
and the resin was washed twice with water. Negative charged
compounds were eluted with 0.8 ml of 1 M NaCl and quantified
in a WinSpectral 1414 liquid scintillation counter (Wallac). When
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before use (0.5 ng of TcTS611/2, rendered ,4000 cpm per hour).
Trans-sialidase Inhibition Assay (TIA). Culture
supernatants from transformed HB2151 clones, purified phages,
llama serum or purified VHHs, were assayed for their inhibitory
activity on TcTS. Purified recombinant TcTS enzyme or TcTS
derived from trypomastigotes (similar to the infective form of the
parasite present in the mammalian host) were preincubated for
30 min with the sample to be tested, and the remnant ability to
transfer the sialyl residues from sialyllactose to [D-glucose-1-
14C]
lactose was evaluated as described above. The different quantities
used of each sample (llama serum, phage-VHHs or purified
VHHs) are indicated in the corresponding figure. Results are
expressed in percentage of inhibition of trans-sialidase activity.
Reaction measured without addition of any inhibitor was
considered as 0% of inhibition (100% of enzymatic activity).
D o ts p o ta s s a y . Recombinant proteins (300 ng each) were
spotted onto nitrocellulose membrane as indicated in Figure 3C.
Filters were blocked for 2 hs with 5% SM-TBS, and when indicated,
probed with a second purified protein for assessment of interactions.
They were subsequently incubated with different antisera for 1 h
(mouse anti-histidine serum (Sigma) at 1:500 dilution or rabbit anti-
TcTS serum at 1:1,000 dilution) and washing 3 times with TBS after
each treatment. Filters were processed using anti-mouse or rabbit
horseradish peroxidase (HRP)-conjugated secondary antibodies
(Gibco) at 1:8,000 dilution, and positive signals were revealed by
chemiluminescence (Super Signal West Pico Chemiluminescent,
Pierce).
Affinity measurements. Kinetic analyses of the interactions
were determined with IAsys Biosensor instrument
(ThermoLabSystems). Each purified monoclonal VHH was
immobilized in 10 mM sodium acetate pH 5.0 on a
carboxymethylated dextrane layer using EDC/NHS chemistry
following the manufacture instructions. 10–30 ng of VHH were
immobilized. For kinetic constant determination, dilutions of
TcTS in PBS-0.05% Tween were added to the cuvette. Binding
traces were recorded for at least 7 different concentrations.
Measurements in present of DANA were done adding DANA to
the cuvette before TcTS. The addition of DANA does not induce
any change in the signal. Association and dissociation rate
constants were calculated using the FASTFIT software.
Immunoprecipitation of natural TcTS. Crude extracts of
2610
8 Cl-Brener trypomastigotes were incubated with purified
anti-SAPA antibodies raised in mice (8 mg, ON, 4uC) followed by
protein A-Sepharosa beads (75 ml, 4 hs, 4uC, Sigma). Beads were
washed and conserved in Tris-HCl 20 mM, pH 7.6.
Deglycosylation of TcTS. PNGase F eliminates the entire
N-glycosylation trees from GlcNAc of asparagine residues.
Immunoprecipitated TcTS was incubated for 48 hs, at 37uC, in
presence of PNGaseF (Biolabs) or in absence as a control of
possible activity losses. Natural TcTS, deglycosylated or not, were
diluted to rendering between 2000–3000 CPM/h (100% of
activity) and assayed by TIA.
Cloning of Trypomastigote TcTSs. cDNA or Genomic
DNA from CL-Brener trypomastigotes were amplified by PCR
using primers designed to amplify the entire globular core of TcTS
gene family. Their sequences are LAPTSTE:G GA ATT CGC
TAG CCT GGC ACC CGG ATC GAG CCG A (carrying
EcoRI–NheI restriction sites), TGA: GTG GAA TTC AGG CAC
TCG TGT CGC TGC TGC TGT C (carrying EcoRI restriction
site) or alternatively 39 SAPA: CAG CAG CAA AGC ACC CGC
AC. The PCR product, containing the intrinsic variability of
TcTS family, render a single band (,2000 bp), which was cloned
in pGEM-T Easy vector system (Promega) to further sequencing
and selection of putative active TcTS (criteria based on presence
of Tyr342) [16]. Individual chosen clones were subcloned in
pTrcHisA (Invitrogen) using NheI–EcoRI restriction sites. TcTs
were induced and purified as described above. The activity was
assayed, linear condition of each TcTS clone concentration was
confirmed before inhibition assay take place.
Data Bank accession codes- Sequences of the four TcTS strong
inhibitor VHH clones have been deposited in the GenBank, with
accession numbers from DQ315483 to DQ315486. Active TcTS
clones from T. cruzi Cl-Brener strain have been deposited in the
GenBank, with accession numbers from EU805797 to 805801.
Supporting Information
Table S1 Identity index between amino acid sequences of
different TcTS clones from T. cruzi CL-Brener strain
Found at: doi:10.1371/journal.pone.0003524.s001 (0.11 MB
DOC)
Figure S1 Deglycosylation of immunoprecipitated natural TcTS
with PNGasa F under non-denatured conditions. (A) Coomasie
blue stained SDS-PAGE. The two left lanes show the results of
SBA glycoprotein (soybean agglutinin) used as a control of
PNGasa F activity. In the right lanes, heavy chain (hc)
corresponding to mouse anti-SAPA used to immunoprecipitate
natural TcTS population from trypomastigotes, present in the
same sample used in experiment indicated in panel B, that showed
a lower molecular weight after treatment with PNGasa F. Due to
the low amount of immunoprecipitated protein, TcTS was not
detectable in coomasie blue stained gel. Panel (B) shows a Western
blot of immunoprecipitated TcTS, incubated with anti-SAPA
serum raised in mouse and revealed with the corresponding HRP-
conjugated-anti-serum for chemiluminescence generation. The
arrow is to indicate the TcTS band with a stronger signal (TcTS
display several bands in Western blot) and that has an apparent
lower molecular weight after PNGase F treatment. (+) indicates
incubation with PNGase F and (2) indicates incubation in the
absence of PNGase F.
Found at: doi:10.1371/journal.pone.0003524.s002 (3.18 MB TIF)
Figure S2 Deduced amino acid sequences of entire globular
core of TcTSs, without SAPA repeats, cloned from T. cruzi Cl-
Brener strain. All sequences start with a leucine, that is the first
amino acid residue in the mature natural protein [47]. Amino
acidic residues differing to those present in TcTS611/2 clone are
boxed. Asterisk indicates the putative N-glycosilation site near the
active site, as predicted by NetNglyc 1.0 Server (www.cbs.dtu.dk).
Alignment was performed by http://workbench.sdsc.edu.
Found at: doi:10.1371/journal.pone.0003524.s003 (17.39 MB
TIF)
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